News
Public · Published
Seaport Therapeutics Reports Q3 2026 Net Loss of $26.4 Million and $403.8 Million in Cash
Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, up from $22.5 million a year earlier, as research and development spending rose. It ended September with $403.8 million in cash, cash equivalents and investments, which it expects to fund current operations into 2029.
Published:
Updated:
What happened
Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, up from $22.5 million a year earlier, as research and development spending rose. It ended September with $403.8 million in cash, cash equivalents and investments, which it expects to fund current operations into 2029.
Confirmed
Global impact / market context
Higher research spending contributed to a wider quarterly loss, while the reported cash balance gives Seaport a stated runway into 2029. For investors, clinical progress and spending together matter because trial results may shape future development costs and the company’s need for additional funding.
Analyst inference
The article describes a clinical-stage company reporting losses while funding research and trials from its cash and investments. Positive driving-simulation results for GlyphAllo and the first patient dosed in a GlyphAgo Phase 2a trial provide development updates, but no commercial revenue is reported.
Confirmed
What to watch
- Track whether research and development spending continues to rise, since the article links higher spending to the larger quarterly loss and ongoing clinical work. Analyst inference
- Watch for further GlyphAllo trial updates, including whether the reported driving-simulation result is followed by additional evidence on safety and performance. Analyst inference
- Follow enrollment and progress in the GlyphAgo Phase 2a trial; the article reports its first patient was dosed but gives no further trial results. Confirmed
Evidence
- Original source link unavailable